Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03643224 · ClinicalTrials.gov registry record · NA
DiamondTemp™ System for the Treatment of Persistent Atrial Fibrillation
A NA study, sponsored by Medtronic Cardiac Ablation Solutions.
- Completed
- Registry status
- NA
- Development phase
- 376
- Enrollment target
NCT03643224 is a NA study that has completed, run by Medtronic Cardiac Ablation Solutions. The registered enrollment target is 376 participants.
The verdict
NCT03643224, a NA study, has completed, sponsored by Medtronic Cardiac Ablation Solutions.
- COMPLETED
- Registry status
- NA
- Development phase
- 376 participants
- Enrollment target
Study Summary
The purpose of the Diamond-AF II study is to establish the safety and effectiveness of the DiamondTemp Ablation System for the treatment of drug refractory, symptomatic persistent atrial fibrillation in patients.
Interventions
- DEVICE Radiofrequency Ablation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 376 participants |
| Start Date | 2018-09-19 |
| Est. Completion | 2024-10-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03643224
The ClinicalTrials.gov registry entry for NCT03643224 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 376 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Cardiac Ablation Solutions, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Radiofrequency Ablation is the first listed.
NCT03643224 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03643224 about?
NCT03643224 is a clinical study titled "DiamondTemp™ System for the Treatment of Persistent Atrial Fibrillation". The purpose of the Diamond-AF II study is to establish the safety and effectiveness of the DiamondTemp Ablation System for the treatment of drug refractory, symptomatic persistent atrial fibrillation in patients.
What is the current status of trial NCT03643224?
This trial is currently completed. It is a NA study. The enrollment target is 376 participants. The study started on 2018-09-19. Estimated completion is 2024-10-31.
What interventions are being tested in trial NCT03643224?
The interventions under investigation include: Radiofrequency Ablation (DEVICE).
Who is sponsoring clinical trial NCT03643224?
This trial is sponsored by Medtronic Cardiac Ablation Solutions, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.